REGN financials
Regeneron Pharmaceuticals, Inc. · end-of-day data as of Oct 16, 2026
Regeneron Pharmaceuticals, Inc.
$790.74+20.7%
Buy · 29 analystsPT $859.53 +8.7%
REGN reported revenue of $4.29B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 16.7% from a year earlier. It posted diluted EPS of $12.20, free cash flow of $334M and a net margin of 30.2%.
Valuation
- P/E19.6x
- P/E vs own+18.0%
- P/E vs sector-30.5%
- FCF yield+4.3%
- Market cap$81.41B
Quarterly results
Q2 FY2026: Revenue +16.7% year over year, free cash flow 7.8% of revenue, operating margin 33.1%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $4.29B | 12.20 | $334M | 86.6% | 33.1% | 30.2% |
| Q1 FY2026 | Mar 31, 2026 | $3.61B | 6.75 | $848M | 81.4% | 17.8% | 20.2% |
| Q4 FY2025 | Dec 31, 2025 | $3.88B | 7.86 | $922M | 84.9% | 22.7% | 21.7% |
| Q3 FY2025 | Sep 30, 2025 | $3.75B | 13.62 | $1.42B | 86.1% | 27.3% | 38.9% |
| Q2 FY2025 | Jun 30, 2025 | $3.68B | 12.81 | $968M | 85.6% | 29.4% | 37.9% |
| Q1 FY2025 | Mar 31, 2025 | $3.03B | 7.27 | $774M | 84.7% | 19.5% | 26.7% |
| Q4 FY2024 | Dec 31, 2024 | $3.79B | 8.06 | $996M | 85.1% | 26.1% | 24.2% |
| Q3 FY2024 | Sep 30, 2024 | $3.72B | 11.54 | $1.11B | 86.8% | 31.7% | 36.0% |
| Q2 FY2024 | Jun 30, 2024 | $3.55B | 12.41 | $143M | 86.5% | 30.2% | 40.4% |
| Q1 FY2024 | Mar 31, 2024 | $3.15B | 6.27 | $1.35B | 86.2% | 23.9% | 23.0% |
| Q4 FY2023 | Dec 31, 2023 | $3.43B | 10.19 | $776M | 81.7% | 30.6% | 33.8% |
| Q3 FY2023 | Sep 30, 2023 | $3.36B | 8.89 | $938M | 83.9% | 36.0% | 30.0% |